The U.S. stock market will welcome three new IPOs this November: Aeroméxico, Evommune, and DT House.
Here’s a comprehensive look at their pricing, financial data, EPS outlook, and key takeaways for investors.
📅 November 2025 IPO Calendar Overview
| Date | Company | Ticker | Exchange | Price Range | Sector |
|---|---|---|---|---|---|
| Nov 6 | Grupo Aeroméxico | AERO | NYSE | $18 – $20 | Aviation |
| Nov 7 | Evommune Inc. | EVMN | NYSE | $15 – $17 | Biotech |
| Nov 11 | DT House Limited | DTDT | Nasdaq | $4 – $5 | Online Travel / AI |
Aeroméxico (AERO) — Mexico’s Flag Carrier Returns to the Skies
Company Overview
Grupo Aeroméxico is Mexico’s largest airline, restructured post-pandemic after completing Chapter 11 bankruptcy.
With Delta Air Lines as a joint venture partner, it’s focusing on premium long-haul routes and network expansion.
Financial Snapshot
- FY2023 Revenue: $4.92B
- Operating Income: $716M
- Net Profit (Jan–Sep 2024): $542M
- Debt ratio improving; strong passenger load factors above 90%
Aeroméxico has already achieved profitability thanks to post-pandemic travel recovery.
With stable demand across North and Latin America routes, it’s considered one of the most resilient aviation turnarounds.
IPO Details
- Price Range: $18–$20 per ADS
- Shares Offered: ~11.7M ADS (37% secondary)
- Implied Market Cap: up to $2.9B
- Use of Proceeds: Fleet expansion, digital infrastructure, and customer experience investment
Investment View
- Positive EPS outlook sustained beyond listing
- Risks include fuel cost and FX volatility
- Institutional interest high as the “first major post-reopening airline IPO”
Evommune (EVMN) — A Rising Biotech Player in Inflammatory Diseases
Company Overview
Evommune develops therapies targeting inflammatory and immunologic diseases with two advanced drug candidates:
- EVO756: MRGPRX2 antagonist (Chronic Spontaneous Urticaria, Atopic Dermatitis – Phase 2)
- EVO301: IL-18BP fusion biologic (Atopic Dermatitis, Ulcerative Colitis – Phase 2)
Unlike conventional steroid-based treatments, Evommune focuses on receptor-level immune modulation, a new therapeutic pathway in chronic inflammation.
No commercial revenue yet, but potential licensing deals with major pharma companies could drive long-term value.
Financial Snapshot
- 2023 Net Loss: $34.1M
- 2024 Net Loss: $66.8M
- 2025H1 Net Loss: $28.1M, Accumulated Deficit: $180M
- R&D-driven cost structure, zero revenue so far
EPS Outlook
- Still in clinical Phase 2 → profitability expected 3–4 years away
- Potential turnaround via partnership or out-licensing deal
IPO Details
- Price Range: $15–$17
- Shares: ~9.4M (plus 1.4M option)
- Exchange: NYSE
Investment View
- High-risk, high-reward biotech profile
- Mid-to-long term clinical momentum play
- Success in late-stage data could trigger sharp revaluation
DT House (DTDT) — The AI-Powered Travel Marketplace from Asia to the Middle East
Company Overview
DT House is an online travel platform operating in Hong Kong and the UAE.
It offers hotel, flight, and local transport bookings, integrating AI-driven recommendation systems for better user conversion.
Business Model
- Partners with Trip.com and Alibaba’s Fliggy
- Serves both B2B agents and retail users
- Expanding AI search optimization for profitability
Financial Snapshot
- Small-scale revenue base, low margins
- Not yet profitable, but travel demand rebound supports revenue growth
EPS Outlook
- Short-term profitability unlikely
- AI optimization could enable positive earnings by 2026–2027
IPO Details
- Price Range: $4–$5
- Shares: ~1.9M (plus 15% over-allotment)
- Exchange: Nasdaq Capital Market
Investment View
- Unique “AI + Travel” thematic exposure
- Focus on scalability and partnership growth
- Presence of resale tranche → higher post-listing float risk
Comparative Summary Table
| Metric | AERO | EVMN | DTDT |
|---|---|---|---|
| Sector | Aviation | Biotech | Travel / AI |
| Current Profitability | Profitable | Negative | Negative |
| EPS Outlook | Stable / Positive | 3–4 years | Uncertain |
| Growth Driver | Travel Recovery | Clinical Data | AI Adoption |
| Key Risk | Fuel & FX | Clinical Delay | Thin Margins |
Summary
The November 2025 IPO lineup highlights three dominant global trends:
reopening recovery, biotech innovation, and AI-enabled services.
- Aeroméxico (AERO): Stable earnings and airline recovery play
- Evommune (EVMN): Long-term biotech momentum with upside from Phase 2 data
- DT House (DTDT): AI-powered travel tech with high growth potential but early-stage risk
For short-term stability, Aeroméxico leads.
For long-term growth exposure, Evommune and DT House offer asymmetric potential.
Always review final pricing, lock-up schedules, and institutional allocations before investing.